AbbVie Inc. (ABBV) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
AbbVie’s revenue went from $25.6B in fiscal 2016 to $61.2B in fiscal 2025, growth of about 10.1% a year.
Net income in fiscal 2025 was $4.2B, a net margin of 6.9%; the best year in this period was 2022 with $11.8B.
Over the twelve months to September 30, 2026, revenue was $66.0B and net income $10.3B.
Free cash flow was $17.8B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 9% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.0B | $61.2B | $56.3B | $54.3B | $58.1B | $56.2B | $45.8B | $33.3B | $32.8B | $28.2B | $25.6B |
| Gross profit | $48.7B | $43.0B | $39.4B | $33.9B | $40.6B | $38.8B | $30.4B | $25.8B | $25.0B | $21.2B | $19.8B |
| Operating income | $21.2B | $15.1B | $9.1B | $12.8B | $18.1B | $17.9B | $11.4B | $13.0B | $6.4B | $9.5B | $9.3B |
| Net income | $10.3B | $4.2B | $4.3B | $4.9B | $11.8B | $11.5B | $4.6B | $7.9B | $5.7B | $5.3B | $6.0B |
| EPS (diluted) | $5.81 | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 |
| R&D | $10.0B | $9.1B | $12.8B | $7.7B | $6.5B | $6.9B | $6.4B | $6.4B | $10.3B | $5.0B | $4.4B |
| Revenue growth | — | +8.6% | +3.7% | −6.4% | +3.3% | +22.7% | +37.7% | +1.6% | +16.1% | +10.1% | +12.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $20.1B | $19.0B | $18.8B | $22.8B | $24.9B | $22.8B | $17.6B | $13.3B | $13.4B | $10.0B | $7.0B |
| Capital spending | -$1.2B | -$1.2B | -$974M | -$777M | -$695M | -$787M | -$798M | -$552M | -$638M | -$529M | -$479M |
| Free cash flow | $18.9B | $17.8B | $17.8B | $22.1B | $24.2B | $22.0B | $16.8B | $12.8B | $12.8B | $9.4B | $6.6B |
| Dividends paid | $12.1B | $11.7B | $11.0B | $10.5B | $10.0B | $9.3B | $7.7B | $6.4B | $5.6B | $4.1B | $3.7B |
| Buybacks | $1.5B | $980M | $1.7B | $2.0B | $1.5B | $934M | $978M | $629M | $12.0B | $1.4B | $6.0B |
| Stock-based pay | $927M | $955M | $911M | $747M | $671M | $692M | $753M | $430M | $421M | $365M | $353M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $5.3B | $5.6B | $12.8B | $9.2B | $9.8B | $8.5B | $39.9B | $8.1B | $9.8B | $6.4B |
| Debt | — | $65.4B | $67.7B | $60.1B | $64.0B | $76.9B | $86.0B | $67.6B | $38.7B | $31.4B | $36.8B |
| Equity | — | -$3.3B | $3.3B | $10.4B | $17.3B | $15.4B | $13.1B | -$8.2B | -$8.4B | $5.1B | $4.6B |
| Total assets | — | $134.0B | $135.2B | $134.7B | $138.8B | $146.5B | $150.6B | $89.1B | $59.4B | $70.8B | $66.1B |
| Shares (diluted) | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B | 1.55B | 1.60B | 1.63B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 73.7% | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% | 77.6% | 76.4% | 75.0% | 77.2% |
| Operating margin | 32.2% | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 33.8% | 36.4% |
| Net margin | 15.7% | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% |
| FCF margin | 28.6% | 29.1% | 31.6% | 40.6% | 41.8% | 39.1% | 36.7% | 38.4% | 39.1% | 33.4% | 25.6% |
| ROIC | — | 15.6% | 10.2% | 14.1% | 19.6% | 17.3% | 9.1% | 20.4% | 16.7% | 18.0% | 17.0% |
| ROE | — | -129.2% | 128.7% | 46.9% | 68.6% | 74.9% | 35.3% | -96.5% | -67.3% | 104.2% | 128.4% |
Frequently asked questions
What is AbbVie’s annual revenue?
$61.2B in fiscal 2025 and $66.0B over the twelve months to September 30, 2026.
How much profit does AbbVie make?
Net income was $4.2B in fiscal 2025 (net margin 6.9%).
Is AbbVie’s revenue growing?
Yes: revenue rose 8.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.